Freenome (FRNM) closed at $11.47 on November 3, 2026, down 1.2% from the previous close, on volume of 506,064 shares (30-day average 623,766).
Data as of November 3, 2026.
Market Chameleon (Tue, 20-Oct 7:19 AM ET)
Globe Newswire (Tue, 20-Oct 8:30 AM ET)
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
Globe Newswire (Thu, 15-Oct 4:29 PM ET)
Globe Newswire (Sun, 11-Oct 1:00 PM ET)
Globe Newswire (Wed, 12-Aug 9:00 AM ET)
Market Chameleon (Mon, 27-Jul 5:19 AM ET)
Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.
Freenome trades on the NASDAQ stock market under the symbol FRNM.
As of November 3, 2026, FRNM stock price declined to $11.47 with 506,064 million shares trading.
FRNM has a beta of 1.31, meaning it tends to be more sensitive to market movements. FRNM has a correlation of 0.02 to the broad based SPY ETF.
FRNM has a market cap of $1.23 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that FRNM belongs to (by Net Assets): ARKG, VXF, SCHA, ITOT, ONEQ.
FRNM support price is $10.97 and resistance is $12.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FRNM shares will trade within this expected range on the day.
